Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Yocum

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Journal of Palliative Medicine|December 22, 2007
Assessing the role of human recombinant hyaluronidase in gravity-driven subcutaneous hydration: the INFUSE-LR studyJay R Thomas, Richard C Yocum, Michael F Haller, et al.
Clinical Lung Cancer|January 1, 2004
Placebo-controlled trial of bexarotene, a retinoid x receptor agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small-cell lung cancerN Rizvi, M J Hawkins, P D Eisenberg, et al.
JAMA|October 8, 1982
Septic arthritis caused by Propionibacterium acnesR C Yocum, J McArthur, B G Petty, et al.
Journal of the American Academy of Dermatology|October 25, 2003
Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trialPeter Heald, Marilyn Mehlmauer, Ann G Martin, et al.
The Journal of Urology|November 13, 2012
Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasiaMostafa M Elhilali, Peter Pommerville, Richard C Yocum, et al.
Journal of Pain and Symptom Management|October 13, 2009
The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illnessJay R Thomas, Mark S Wallace, Richard C Yocum, et al.
Pediatric Physical Therapy : the Official Publication of the Section on Pediatrics of the American Physical Therapy Association|October 21, 2006
Interrater reliability of the active-knee-extension test for hamstring length in school-aged childrenD M Rakos, K A Shaw, R L Fedor, et al.
The Journal of Rheumatology|March 3, 2004
Immune activation and depression in women with rheumatoid arthritisAlex J Zautra, David C Yocum, Isidro Villanueva, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2001
Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial resultsM Duvic, K Hymes, P Heald, et al.
Archives of Dermatology|May 18, 2001
Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphomaM Duvic, A G Martin, Y Kim, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Journal of Palliative Medicine|December 22, 2007
Assessing the role of human recombinant hyaluronidase in gravity-driven subcutaneous hydration: the INFUSE-LR studyJay R Thomas, Richard C Yocum, Michael F Haller, et al.
Clinical Lung Cancer|January 1, 2004
Placebo-controlled trial of bexarotene, a retinoid x receptor agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small-cell lung cancerN Rizvi, M J Hawkins, P D Eisenberg, et al.
JAMA|October 8, 1982
Septic arthritis caused by Propionibacterium acnesR C Yocum, J McArthur, B G Petty, et al.
Journal of the American Academy of Dermatology|October 25, 2003
Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trialPeter Heald, Marilyn Mehlmauer, Ann G Martin, et al.
The Journal of Urology|November 13, 2012
Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasiaMostafa M Elhilali, Peter Pommerville, Richard C Yocum, et al.
Journal of Pain and Symptom Management|October 13, 2009
The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illnessJay R Thomas, Mark S Wallace, Richard C Yocum, et al.
Pediatric Physical Therapy : the Official Publication of the Section on Pediatrics of the American Physical Therapy Association|October 21, 2006
Interrater reliability of the active-knee-extension test for hamstring length in school-aged childrenD M Rakos, K A Shaw, R L Fedor, et al.
The Journal of Rheumatology|March 3, 2004
Immune activation and depression in women with rheumatoid arthritisAlex J Zautra, David C Yocum, Isidro Villanueva, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2001
Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial resultsM Duvic, K Hymes, P Heald, et al.
Archives of Dermatology|May 18, 2001
Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphomaM Duvic, A G Martin, Y Kim, et al.
Pageof 3